← Back to Clinical Trials
Recruiting NCT07252362

NCT07252362 LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07252362
Status Recruiting
Phase
Sponsor Zhejiang Cancer Hospital
Condition The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2023-11-11
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
American Gginseng

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2023-11-11 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Researchers will use LCMS Metabolic Analysis to Explore the Effect of American Ginseng on Urine and Plasma in Healthy Individuals Participants will: * Take 3 grams of American Ginseng powder every day for 14 days * Collect the fasting urine samples at the following times at the hospital: On the first day, on the 7th day after taking the medicine, and on the 14th day after taking the medicine. * Collect the fasting Serum samples at the following times at the hospital: On the first day and on the 14th day after taking the medicine. * Have their any adverse effects monitored and evaluated throughout the study.

Eligibility Criteria

* 18 to 45 years old; * The subjects were fully informed about the research process and signed the informed consent form (the subjects had no abnormalities in routine physical examinations, no previous medical history, and no history of drug allergies); ③ During the trial, they were required to have a light diet and were prohibited from consuming alcoholic and caffeinated beverages;

Contact & Investigator

Central Contact

guan ai Bao, Master

✉ doctorbga@126.com

📞 +8615968857341

Principal Investigator

guan ai Bao, Master

STUDY DIRECTOR

Zhejiang Cancer Hospital

Frequently Asked Questions

Who can join the NCT07252362 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07252362 currently recruiting?

Yes, NCT07252362 is actively recruiting participants. Contact the research team at doctorbga@126.com for enrollment information.

Where is the NCT07252362 trial being conducted?

This trial is being conducted at Hangzhou, China.

Who is sponsoring the NCT07252362 clinical trial?

NCT07252362 is sponsored by Zhejiang Cancer Hospital. The principal investigator is guan ai Bao, Master at Zhejiang Cancer Hospital. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology